Aspirin for Primary and Secondary Prevention of Cardiovascular Disease: Time to Stop?
John G.F. Cleland
Abstract
Comment on: Efficacy and Safety of Aspirin for Primary Cardiovascular Risk Prevention in Younger and Older Age: An Updated Systematic Review and Meta-analysis of 173,810 Subjects from 21 Randomized StudiesThromb Haemost 2022; 122(03): 445-455DOI: 10.1055/a-1667-7427
Topics & Concepts
MedicineAspirinPrimary preventionSecondary preventionRandomized controlled trialDiseaseMeta-analysisInternal medicineCardiologyIntensive care medicineAntiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction ResearchLipoproteins and Cardiovascular Health